Featured
News
Drugmakers that dominate the world's insulin market must scale up access efforts globally
06 October 2022
Amsterdam Session on securing worldwide access to diabetes care by 2030
On 9 April 2024, the Access to Medicine Foundation’s will convene an Amsterdam Session focusing on diabetes care. This event follows on from two previous events hosted by the Foundation's Diabetes Care Programme in 2022 and 2023, both of which were solutions-focused forums for discussion and information sharing.
Date
09 April 2024
Location
Amsterdam, the Netherlands
DATE
Tuesday 9 April 2024
LOCATION
Amsterdam, the Netherlands
FORMAT
In-person (invitation only)
FORMAT
This is a closed event held under the Chatham House Rule. If you are interested in joining Foundation events in the future, please contact Camille Creisson.
Having already hosted two successful Amsterdam Sessions in 2022 and 2023 respectively, the Access to Medicine Foundation’s Diabetes Care Programme will convene another session in 2024, titled: “Securing worldwide access to diabetes care by 2030: Spotlight on strategies and solutions to close the equity gap”. As with the previous sessions, the central focus remains on ensuring sustainable access to diabetes care in low- and middle-income countries (LMICs).
Building on ongoing dialogues, this third event is poised to provide a dynamic platform to review progress and collectively address the ongoing challenges in diabetes care as an interconnected ecosystem. The programme will specifically focus on recent advancements in companies' access strategies and their impact on access, opportunities for device manufacturers in LMIC markets, and collaborative efforts to shape a coordinated supply chain for diabetes care products.
Representatives from insulin and device manufacturers, international organisations, distributors, implementing partners and local governments will be participating in the upcoming session, which will be a closed event held under the Chatham House Rule.
Following the session, the Foundation will draw up a public report that includes a set of tangible, practical next steps and recommendations for the private sector and other stakeholders to sustainably ensure access to insulin, glucose monitoring devices, and associated commodities that are essential for people living with diabetes in LMICs.
